News headlines about Eyenovia (NASDAQ:EYEN) have trended somewhat negative on Thursday, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eyenovia earned a news sentiment score of -0.04 on Accern’s scale. Accern also assigned media stories about the company an impact score of 43.8525027948071 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities research analysts recently weighed in on EYEN shares. Ladenburg Thalmann Financial Services began coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They set a “buy” rating and a $35.00 price target for the company. Roth Capital initiated coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They issued a “buy” rating and a $20.00 target price for the company.
Eyenovia stock opened at $8.50 on Thursday. Eyenovia has a 1-year low of $7.32 and a 1-year high of $10.74.
COPYRIGHT VIOLATION NOTICE: “Eyenovia (EYEN) Earns Daily Media Sentiment Rating of -0.04” was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://baseballnewssource.com/2018/03/22/somewhat-negative-media-coverage-somewhat-unlikely-to-impact-eyenovia-eyen-stock-price/1926334.html.
Eyenovia Company Profile
Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.